TABLE OF CONTENTS
1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.3 OVERVIEW OF GLOBAL DRY EYE SYNDROME MARKET 37
1.4 CURRENCY AND PRICING 39
1.5 LIMITATIONS 39
1.6 MARKETS COVERED 39
2 MARKET SEGMENTATION 43
2.1 MARKETS COVERED 43
2.2 GLOBAL DRY EYE SYNDROME MARKET: GEOGRAPHICAL SCOPE 44
2.3 YEARS CONSIDERED FOR THE STUDY 45
2.4 CURRENCY AND PRICING 45
2.5 DBMR TRIPOD DATA VALIDATION MODEL 46
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 49
2.7 DBMR MARKET POSITION GRID 50
2.8 DBMR VENDOR SHARE ANALYSIS 52
2.9 MULTIVARIATE MODELING 53
2.10 PRODUCTS LIFELINE CURVE 53
2.11 SECONDARY SOURCES 54
2.12 ASSUMPTIONS 54
3 MARKET OVERVIEW 55
3.1 DRIVERS 57
3.1.1 INCREASING PREVALENCE OF DRY EYE DISEASES 57
3.1.2 CHANGING GEOGRAPHICAL TRENDS TO DRIVE THE MARKET 57
3.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE 58
3.1.4 RISING GERIATRIC POPULATION ACROSS THE WORLD 58
3.1.5 INCREASE IN LASIK SURGERY AND USAGE OF CONTACT LENSES 59
3.2 RESTRAINTS 60
3.2.1 STRINGENT REGULATORY PROCESS 60
3.2.2 UNMET MEDICAL NEEDS 60
3.3 OPPORTUNITIES 61
3.3.1 EMERGING MARKET PRESENTS SIGNIFICANT OPPORTUNITIES 61
3.3.2 DEVELOPMENT OF NOVEL TECHNOLOGIES 61
3.4 CHALLENGE 62
3.4.1 INCREASING NUMBER OF PLAYERS 62
4 EXECUTIVE SUMMARY 63
5 PREMIUM INSIGHTS 67
6 PIPELINE ANALYSIS 69
6.1 OVERVIEW 69
6.2 MARKETED DRUGS 69
6.3 APPROVED/FILED DRUGS 73
6.4 PHASE III TRIAL CANDIDATES 73
6.5 PHASE II TRIAL CANDIDATES 74
6.6 PHASE I TRIAL CANDIDATES 76
6.7 OTHERS 76
7 GLOBAL DRY EYE SYNDROME MARKET, BY PRODUCT TYPE 77
7.1 OVERVIEW 78
7.2 TEAR STIMULATORS 79
7.2.1 PILOCARPINE 80
7.2.2 CYCLOSPORINE 80
7.2.3 LIFITEGRAST 80
7.3 ARTIFICIAL TEARS 80
7.3.1 SECRETAGOGUE 80
7.3.2 OTHERS 81
8 GLOBAL DRY EYE SYNDROME MARKET, BY DOSAGE TYPE 82
8.1 OVERVIEW 83
8.2 LIQUID 84
8.2.1 SOLUTIONS 85
8.2.2 EMULSIONS 85
8.2.3 SUSPENSIONS 86
8.3 SEMI-SOLID 86
8.3.1 GEL 87
8.3.2 OINTMENT 88
8.4 OTHERS 88
9 GLOBAL DRY EYE SYNDROME MARKET, BY DRUG CLASS 89
9.1 OVERVIEW 90
9.2 ANTI-INFLAMMATORY 91
9.3 LUBRICATING AGENT 91
9.4 ANTI-INFECTIVE 92
9.5 ANTI-ALLERGIC 93
9.6 CHOLINERGIC 94
9.7 OTHERS 94
10 GLOBAL DRY EYE SYNDROME MARKET, BY DOSE 96
10.1 OVERVIEW 97
10.2 MULTI DOSE 98
10.3 UNIT DOSE 99
11 GLOBAL DRY EYE SYNDROME MARKET, BY MEDICATION TYPE 100
11.1 OVERVIEW 101
11.2 PRESCRIPTION (RX) DRUGS 102
11.3 OVER THE COUNTER (OTC) DRUGS 103
12 GLOBAL DRY EYE SYNDROME MARKET, BY CONTAINER TYPE 104
12.1 OVERVIEW 105
12.2 UNIT DOSE VIALS 106
12.3 BOTTLES 106
12.4 TUBES 107
13 GLOBAL DRY EYE SYNDROME MARKET, BY PACKAGING TYPE 108
13.1 OVERVIEW 109
13.2 PLASTIC 110
13.3 GLASS 111
13.4 ALUMINIUM 112
14 GLOBAL DRY EYE SYNDROME MARKET, BY TYPE 113
14.1 OVERVIEW 114
14.2 GENERIC DRUG 115
14.3 BRANDED 115
14.3.1 RESTASIS 116
14.3.2 XIIDRA 116
14.3.3 REFRESH 117
14.3.4 SYSTANE 117
14.3.5 TEARS NATURALE 117
14.3.6 IKERVIS 117
14.3.7 DIQUAS 117
14.3.8 OTHERS 117
?
15 GLOBAL DRY EYE SYNDROME MARKET, BY END USER 118
15.1 OVERVIEW 119
15.2 HOME HEALTHCARE 120
15.3 HOSPITALS 121
15.4 CLINICS 121
15.5 OTHERS 122
16 GLOBAL DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL 123
16.1 OVERVIEW 124
16.2 HOSPITAL PHARMACIES 125
16.3 RETAIL PHARMACIES 125
16.4 ONLINE PHARMACIES 126
16.5 OTHERS 127
17 GLOBAL DRY EYE SYNDROME MARKET BY GEOGRAPHY 128
17.1 OVERVIEW 128
17.2 NORTH AMERICA 133
17.2.1 U.S. 140
17.2.2 CANADA 144
17.2.3 MEXICO 148
17.3 EUROPE 152
17.3.1 GERMANY 160
17.3.2 U.K. 164
17.3.3 FRANCE 168
17.3.4 ITALY 172
17.3.5 SPAIN 176
17.3.6 RUSSIA 180
17.3.7 NETHERLANDS 184
17.3.8 SWITZERLAND 189
17.3.9 BELGIUM 194
17.3.10 TURKEY 198
17.3.11 REST OF EUROPE 202
17.4 ASIA-PACIFIC 203
17.4.1 JAPAN 211
17.4.2 CHINA 216
17.4.3 INDIA 221
17.4.4 SOUTH KOREA 225
17.4.5 AUSTRALIA 230
17.4.6 SINGAPORE 235
17.4.7 THAILAND 240
17.4.8 MALAYSIA 245
17.4.9 INDONESIA 250
17.4.10 PHILIPPINES 255
17.4.11 REST OF APAC 259
17.5 SOUTH AMERICA 260
17.5.1 BRAZIL 267
17.5.2 REST OF SOUTH AMERICA 271
17.6 MIDDLE EAST AND AFRICA 272
17.6.1 SOUTH AFRICA 279
17.6.2 REST OF MIDDLE EAST AND AFRICA 283
18 GLOBAL DRY EYE SYNDROME MARKET, COMPANY LANDSCAPE 284
18.1 COMPANY SHARE ANALYSIS: GLOBAL 284
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 285
18.3 COMPANY SHARE ANALYSIS: EUROPE 286
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 287
19 SWOT ANALYSIS 288
19.1 DATA BRIDGE MARKET RESEARCH ANALYSIS- 290
20 COMPANY PROFILE 291
20.1 ALLERGAN 291
20.1.1 COMPANY SNAPSHOT 291
20.1.2 REVENUE ANALYSIS 291
20.1.3 COMPANY SHARE ANALYSIS 292
20.1.4 GEOGRAPHICAL PRESENCE 292
20.1.5 PRODUCT PORTFOLIO 293
20.1.6 RECENT DEVELOPMENTS 294
20.2 NOVARTIS AG 296
20.2.1 COMPANY OVERVIEW 296
20.2.2 REVENUE ANALYSIS 296
20.2.3 COMPANY SHARE ANALYSIS 297
20.2.4 GEOGRAPHICAL PRESENCE 297
20.2.5 PRODUCT PORTFOLIO 298
20.2.6 RECENT DEVELOPMENT 298
20.3 BAUSCH & LOMB INCORPORATED. 299
20.3.1 COMPANY SNAPSHOT 299
20.3.2 REVENUE ANALYSIS 299
20.3.3 COMPANY SHARE ANALYSIS 300
20.3.4 GEOGRAPHICAL PRESENCE 300
20.3.5 PRODUCT PORTFOLIO 301
20.3.6 RECENT DEVELOPMENT 302
20.4 SANTEN PHARMACEUTICAL CO., LTD. 303
20.4.1 COMPANY OVERVIEW 303
20.4.2 REVENUE ANALYSIS 303
20.4.3 COMPANY SHARE ANALYSIS 304
20.4.4 GEOGRAPHICAL PRESENCE 304
20.4.5 PRODUCT PORTFOLIO 305
20.4.6 RECENT DEVELOPMENT 305
20.5 JOHNSON & JOHNSON SERVICES, INC. 306
20.5.1 COMPANY SNAPSHOT 306
20.5.2 REVENUE ANALYSIS 306
20.5.3 COMPANY SHARE ANALYSIS 307
20.5.4 GEOGRAPHICAL PRESENCE 307
20.5.5 PRODUCT PORTFOLIO 308
20.5.6 RECENT DEVELOPMENTS 309
20.6 AKORN, INCORPORATED 310
20.6.1 COMPANY OVERVIEW 310
20.6.2 REVENUE ANALYSIS 310
20.6.3 GEOGRAPHICAL PRESENCE 311
20.6.4 PRODUCT PORTFOLIO 311
20.6.5 RECENT DEVELOPMENT 312
20.7 ALCON INC 313
20.7.1 COMPANY SNAPSHOT 313
20.7.2 REVENUE ANALYSIS 313
20.7.3 GEOGRAPHICAL PRESENCE 314
20.7.4 PRODUCT PORTFOLIO 314
20.7.5 RECENT DEVELOPMENT 315
20.8 ALEMBIC PHARMACEUTICALS LIMITED 316
20.8.1 COMPANY SNAPSHOT 316
20.8.2 REVENUE ANALYSIS 316
20.8.3 GEOGRAPHICAL PRESENCE 317
20.8.4 PRODUCT PORTFOLIO 317
20.8.5 RECENT DEVELOPMENTS 318
20.9 CARDINAL HEALTH 319
20.9.1 COMPANY SNAPSHOT 319
20.9.2 REVENUE ANALYSIS 319
20.9.3 GEOGRAPHICAL PRESENCE 320
20.9.4 PRODUCT PORTFOLIO 320
20.9.5 RECENT DEVELOPMENTS 320
20.10 CIPLA INC 321
20.10.1 COMPANY SNAPSHOT 321
20.10.2 REVENUE ANALYSIS 321
20.10.3 GEOGRAPHICAL PRESENCE 322
20.10.4 PRODUCT PORTFOLIO 322
20.10.5 RECENT DEVELOPMENTS 322
20.11 HORUS PHARMA 323
20.11.1 COMPANY OVERVIEW 323
20.11.2 GEOGRAPHICAL PRESENCE 323
20.11.3 PRODUCT PORTFOLIO 324
20.11.4 RECENT DEVELOPMENT 325
20.12 HUBRX 326
20.12.1 COMPANY SNAPSHOT 326
20.12.2 PRODUCT PORTFOLIO 326
20.12.3 RECENT DEVELOPMENTS 326
20.13 NOVALIQ GMBH 327
20.13.1 COMPANY OVERVIEW 327
20.13.2 GEOGRAPHICAL PRESENCE 327
20.13.3 PRODUCT PORTFOLIO 328
20.13.4 RECENT DEVELOPMENT 328
20.14 PERRIGO COMPANY PLC 329
20.14.1 COMPANY SNAPSHOT 329
20.14.2 REVENUE ANALYSIS 329
20.14.3 GEOGRAPHICAL PRESENCE 330
20.14.4 PRODUCT PORTFOLIO 330
20.14.5 RECENT DEVELOPMENT 331
20.15 PRESTIGE CONSUMER HEALTHCARE, INC. 332
20.15.1 COMPANY SNAPSHOT 332
20.15.2 REVENUE ANALYSIS 332
20.15.3 PRODUCT PORTFOLIO 333
20.15.4 RECENT DEVELOPMENTS 333
20.16 ROHTO PHARMACEUTICAL CO., LTD. 334
20.16.1 COMPANY SNAPSHOT 334
20.16.2 REVENUE ANALYSIS 334
20.16.3 GEOGRAPHICAL PRESENCE 335
20.16.4 PRODUCT PORTFOLIO 335
20.16.5 RECENT DEVELOPMENT 337
20.17 SENJU PHARMACEUTICAL CO. LTD. 338
20.17.1 COMPANY OVERVIEW 338
20.17.2 REVENUE ANALYSIS 338
20.17.3 GEOGRAPHICAL PRESENCE 339
20.17.4 PRODUCT PORTFOLIO 339
20.17.5 RECENT DEVELOPMENT 342
20.18 SUN PHARMACEUTICAL INDUSTRIES LTD. 343
20.18.1 COMPANY SNAPSHOT 343
20.18.2 REVENUE ANALYSIS 343
20.18.3 GEOGRAPHICAL PRESENCE 344
20.18.4 PRODUCT PORTFOLIO 344
20.19 TEVA PHARMACEUTICAL INDUSTRIES LTD. 345
20.19.1 COMPANY SNAPSHOT 345
20.19.2 REVENUE ANALYSIS 345
20.19.3 GEOGRAPHICAL PRESENCE 346
20.19.4 PRODUCT PORTFOLIO 346
20.19.5 RECENT DEVELOPMENT 347
20.19.6 RECENT DEVELOPMENTS 347
20.20 VISUFARMA 348
20.20.1 COMPANY OVERVIEW 348
20.20.2 GEOGRAPHICAL PRESENCE 348
20.20.3 PRODUCT PORTFOLIO 349
20.20.4 RECENT DEVELOPMENTS 350
21 REFERENCES 351
22 QUESTIONNAIRE 353
23 RELATED REPORTS 359